share_log

HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Maintains $20 Price Target

Benzinga ·  Mar 28 01:49

HC Wainwright & Co. analyst Patrick Trucchio maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $20 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment